QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Page |
||||||
PART 1 - |
||||||
Item 1. | ||||||
1 | ||||||
2 | ||||||
3 | ||||||
4 | ||||||
5 | ||||||
Item 2. | 17 | |||||
Item 3. | 21 | |||||
Item 4. | 21 | |||||
PART II - |
||||||
Item 1. | 21 | |||||
Item 1A. | 21 | |||||
Item 2. | 22 | |||||
Item 3. | 22 | |||||
Item 4. | 22 | |||||
Item 5. | 22 | |||||
Item 6. | 22 | |||||
23 |
ASSETS |
||||
Current assets: |
||||
Cash |
$ | |||
Prepaid expenses |
||||
Total current assets |
||||
Deferred offering costs |
||||
Total Assets |
$ |
|||
LIABILITIES AND STOCKHOLDER’S EQUITY |
||||
Current liabilities |
||||
Accrued offering costs |
$ | |||
Accrued expenses |
||||
Promissory note - related party |
||||
Total Liabilities |
||||
Commitments (see Note 6) |
||||
Stockholder’s Equity |
||||
Preferred stock, $ |
||||
Class A common stock, $ |
||||
Class B common stock, $ (1) |
||||
Additional paid-in capital |
||||
Accumulated deficit |
( |
) | ||
Total Stockholder’s Equity |
||||
TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY |
$ |
|||
(1) |
Includes up to |
Three Months Ended June 30, 2021 |
For the Period from February 2, 2021 (Inception) Through June 30, 2021 |
|||||||
Formation and operating costs |
$ | $ | ||||||
Net loss |
$ |
( |
) |
$ |
( |
) | ||
Weighted average shares outstanding, basic and diluted (1) |
||||||||
Basic and diluted net loss per common share |
$ |
$ |
||||||
(1) |
Excludes up to |
Class B Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total Stockholder’s Equity |
|||||||||||||||||
Shares |
Amount |
|||||||||||||||||||
Balance at February 2, 2021 (inception) |
$ | $ | $ | $ | ||||||||||||||||
Issuance of Class B common stock to Sponsor (1) |
||||||||||||||||||||
Net loss |
— | ( |
) | ( |
) | |||||||||||||||
Balance at March 31, 2021 |
( |
) |
||||||||||||||||||
Net loss |
— | ( |
) | ( |
) | |||||||||||||||
Balance at June 30, 2021 |
$ | $ | $ | ( |
) | $ | ||||||||||||||
(1) |
Includes up to |
Cash Flows from Operating Activities: |
||||
Net loss |
$ | ( |
) | |
Changes in operating assets and liabilities: |
||||
Prepaid expenses |
( |
) | ||
Accrued expenses |
||||
Net cash used in operating activities |
( |
) | ||
Cash Flows from Financing Activities: |
||||
Proceeds from sale of Class B common stock to Sponsor |
||||
Proceeds from promissory note - related party |
||||
Payment of offering costs |
( |
) | ||
Net cash provided by financing activities |
||||
Net Change in Cash |
||||
Cash - Beginning of period |
||||
Cash - End of period |
$ | |||
Non-cash investing and financing activities |
||||
Deferred offering included in accrued offering costs |
$ | |||
• | in whole and not in part; |
• | at a price of $ |
• | upon not less than |
• | if, and only if, the reported last reported sale price of the Class A common stock for any |
• | in whole and not in part; |
• | at a price of $ |
• | if the closing price of the Class A common stock for any |
* | Filed herewith. |
** | Furnished. |
Healthwell Acquisition Corp. I | ||||||
Date: September 14, 2021 | By: | /s/ Alyssa J. Rapp | ||||
Alyssa J. Rapp | ||||||
Chief Executive Officer | ||||||
Healthwell Acquisition Corp. I | ||||||
Date: September 14, 2021 | By: | /s/ Tracy Wan | ||||
Tracy Wan | ||||||
Chief Financial Officer |